Form 4: Evommune CSO Jeegar Patel Receives Stock Option Grant

Evommune, Inc. Chief Scientific Officer Jeegar Patel was granted 69,315 employee stock options on April 16, 2026.

Summary

• Jeegar Patel, Chief Scientific Officer of Evommune, Inc., received a grant of 69,315 employee stock options.
• The options have an exercise price of $26.77 per share.
• The grant follows a standard vesting schedule: 25% vests on the first anniversary of the grant date, with the remainder vesting in 36 equal monthly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Aligns the interests of the Chief Scientific Officer with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon the exercise of these options.

Risks

• Future dilution of equity if options are exercised.
• Dependence on the reporting person's continuous service to satisfy vesting requirements.

Future Outlook

The options vest over a four-year period, incentivizing the Chief Scientific Officer to remain with the company through at least April 2030.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for talent retention and performance alignment, particularly for roles critical to R&D pipelines.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• The use of stock options as a primary retention tool is common among mid-cap and growth-stage pharmaceutical companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of 25% of the options on April 16, 2027.
• Commencement of monthly vesting for the remaining 75% of options thereafter.

Key Dates

Keywords

Evommune, EVMN, Form 4, Insider Trading, Stock Options, Chief Scientific Officer